Table 2 Main features of studies for prognosis analysis
Author (ref.) year | Country | CircRNA | Tumor type | Expression | Assay methods | Case | Cut-offvalue | Tumor stage | High level | Low level | Survival analysis | HR | 95%CI | HR availability | Follow-up months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zhu [14] 2017 | China | circ-BRAF | glioma | down-regulation | qRT-PCR | 68 | NA | grade(I-IV) | 33 | 35 | OS | 4.13 | 1.79–9.56 | K-M curve | 60 |
Wang [15] 2018 | China | circ-0001649 | glioma | down-regulation | qRT-PCR | 64 | NA | grade(I-IV) | 32 | 32 | OS | 2.012 | 1.012–4 | Reported | 60 |
Qu [16] 2019 | China | circ-0079593 | glioma | up-regulation | qRT-PCR | 60 | mean | grade(I-IV) | 30 | 30 | OS | 2.21 | 1.023–4.772 | Reported | 60 |
Lv [17] 2020 | China | circ-EPB41L5 | GBM | down-regulation | qRT-PCR | 45 | median | grade (IV) | 23 | 22 | OS | 3.401 | 1.388–8.88 | Reported | 45 |
Duan [18] 2018 | China | circ-0074362 | glioma | up-regulation | qRT-PCR | 62 | NA | grade(I-IV) | 30 | 32 | OS | 2.695 | 1.054–6.897 | Reported | 56 |
Zhang [19] 2019 | China | circ-0029426 | glioma | up-regulation | qRT-PCR | 59 | mean | grade(I-IV) | 31 | 28 | OS | 2.007 | 1.006–4.002 | Reported | 60 |
Yang [20] 2019 | China | circ-POSTN | glioma | up-regulation | qRT-PCR | 58 | mean | grade(I-IV) | 29 | 29 | OS | 2.1 | 0.74–5.91 | K-M curve | 60 |
Yang [21] 2019 | China | circ-0034642 | glioma | up-regulation | qRT-PCR | 68 | mean | grade(I-IV) | 36 | 32 | OS | 1.75 | 0.84–3.63 | K-M curve | 60 |
Wang [22] 2019 | China | circ-0005198 | glioma | up-regulation | qRT-PCR | 44 | fold change | grade(I-IV) | 22 | 22 | OS | 2.47 | 0.66–9.2 | K-M curve | 60 |
Meng [23] 2019 | China | circ-SCAF11 | glioma | up-regulation | qRT-PCR | 40 | NA | grade(I-IV) | 20 | 20 | OS | 1.64 | 0.59–4.59 | K-M curve | 60 |
Lyu [10] 2020 | China | circ-0013520 | glioma | up-regulation | qRT-PCR | 92 | mean | grade(I-IV) | 40 | 52 | OS | 1.85 | 0.98–3.48 | K-M curve | 31 |
Lyu [10] 2020 | China | circ-0004379 | glioma | up-regulation | qRT-PCR | 92 | mean | grade(I-IV) | 42 | 50 | OS | 1.65 | 0.87–3.11 | K-M curve | 30 |
Lu [24] 2019 | China | circ-0001730 | glioma | up-regulation | qRT-PCR | 99 | NA | grade(I-IV) | 49 | 50 | OS | 1.55 | 0.29–8.11 | K-M curve | 24 |
Liu [25] 2020 | China | circ-CDC45 | glioma | up-regulation | qRT-PCR | 50 | median | grade(I-IV) | 25 | 25 | OS | 1.78 | 0.9–3.55 | K-M curve | 60 |
Ding [26] 2019 | China | circ-NFIX | glioma | up-regulation | qRT-PCR | 64 | NA | grade(I-IV) | 36 | 28 | OS | 0.87 | 0.17–4.46 | K-M curve | 60 |
Chen [27] 2018 | China | circ-0000177 | glioma | up-regulation | qRT-PCR | 62 | NA | grade(I-IV) | 26 | 36 | OS | 2.05 | 0.52–8.1 | K-M curve | 60 |
Chen [28] 2020 | China | circ-0074026 | glioma | up-regulation | qRT-PCR | 60 | mean | grade(I-IV) | 30 | 30 | OS | 2.6 | 1.37–4.94 | K-M curve | 60 |
Li [35] 2018 | China | circ-ITCH | glioma | down-regulation | qRT-PCR | 60 | NA | grade(I-IV) | 31 | 29 | OS | 2.326 | 1.204–5.431 | Reported | 80 |
Peng [36] 2019 | China | circ-CPA4 | glioma | up-regulation | qRT-PCR | 73 | average | grade(I-IV) | 35 | 38 | OS | 3.98 | 1.23–12.94 | K-M curve | 42 |